- Home
- TCRX vs RMI Comparison
TCRX vs RMI Comparison
Compare TCRX & RMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- RMI
- Stock Information
- Founded
- TCRX 2018
- RMI 2018
- Country
- TCRX United States
- RMI United States
- Employees
- TCRX N/A
- RMI N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- RMI Finance/Investors Services
- Sector
- TCRX Health Care
- RMI Finance
- Exchange
- TCRX Nasdaq
- RMI Nasdaq
- Market Cap
- TCRX 91.7M
- RMI 88.8M
- IPO Year
- TCRX 2021
- RMI N/A
- Fundamental
- Price
- TCRX $1.79
- RMI $13.91
- Analyst Decision
- TCRX Strong Buy
- RMI
- Analyst Count
- TCRX 6
- RMI 0
- Target Price
- TCRX $9.50
- RMI N/A
- AVG Volume (30 Days)
- TCRX 255.2K
- RMI 17.4K
- Earning Date
- TCRX 08-12-2025
- RMI 01-01-0001
- Dividend Yield
- TCRX N/A
- RMI 7.28%
- EPS Growth
- TCRX N/A
- RMI N/A
- EPS
- TCRX N/A
- RMI N/A
- Revenue
- TCRX $6,961,000.00
- RMI N/A
- Revenue This Year
- TCRX $159.20
- RMI N/A
- Revenue Next Year
- TCRX N/A
- RMI N/A
- P/E Ratio
- TCRX N/A
- RMI N/A
- Revenue Growth
- TCRX N/A
- RMI N/A
- 52 Week Low
- TCRX $1.02
- RMI $13.05
- 52 Week High
- TCRX $6.23
- RMI $17.37
- Technical
- Relative Strength Index (RSI)
- TCRX 54.34
- RMI 39.35
- Support Level
- TCRX $1.60
- RMI $13.71
- Resistance Level
- TCRX $1.86
- RMI $14.22
- Average True Range (ATR)
- TCRX 0.10
- RMI 0.14
- MACD
- TCRX 0.00
- RMI 0.00
- Stochastic Oscillator
- TCRX 70.37
- RMI 39.22
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.